Biopharma funding for CME courses is on the upswing, according to a new report from the Accreditation Council for Continuing Medical Education. The group took a look at the industry's payments for CME and found that investments increased slightly by 2.4% to $675.9 million in 2014--the first jump since 2007.
Big Pharma's funding of CME classes has drawn its fair share of controversy, with some arguing that industry endorsement could unfairly sway docs' prescribing decisions. Now, another voice is joining the growing chorus of discontent as hotel workers are campaigning to end the practice.
Last week, updated data on pharma's payments to doctors hinted at some pullback. Some physicians apparently are backing away from doing pharma work because of increased scrutiny of those
What drug information source influences doctors most? Perhaps not surprisingly, CME courses are more likely to win physicians over to new treatments, compared with pharma-sponsored dinners for
Over the past couple of years, we've seen an outcry over pharma-industry funding for CME. Indeed, an HHS inspector general told Congress that industry funding has "bastardized" continuing medical
Pfizer and Stanford University are teaming up to develop new CME courses. That's nothing new; drug companies fund new CME all the time. What is new is that Stanford will use $3 million in Pfizer
As some big-name hospitals and drugmakers back away from industry-funded medical education, the Canadian Medical Association has anted up. The CMA has teamed up with Pfizer on a nationwide
GlaxoSmithKline is taking another step back from the drugmaker influence game. The company won't fund commercial CME programs anymore. Instead, starting next year, it will back only medical education
According to a report released by the Senate Special Committee on Aging, Merck and Schering-Plough spent almost $60 million over four years (from January 2004 to January 2008) on continuing medical
Continuing medical education (CME) has been bastardized by pharma funding, an HHS inspector general told Congress, and needs a complete overhaul. Lewis Morris, chief counsel for the HHS office of